Clinical trial · Observational
Molecular Profiling for Risk Stratification in Appendiceal Cancer
Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appendiceal Adenocarcinoma | Appendix Adenocarcinoma | ALIAS | 0.90 |
| Appendiceal Cancer | Malignant Appendix Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA Methylation Profiling | Diagnostic Test | — | UNRESOLVED |
| m6A Epitranscriptomic Profiling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Appendiceal Cancer Cohort
- description
- Patients with histologically confirmed appendiceal cancer whose archived tumor tissue specimens and clinicopathologic data are available for integrated DNA methylation and m6A epitranscriptomic profiling.
- interventionNames
- Diagnostic Test: DNA Methylation Profiling
- Diagnostic Test: m6A Epitranscriptomic Profiling
- label
- Benign Appendix Reference Cohort
- description
- Individuals with benign or normal appendix tissue specimens used as non-malignant reference samples for comparison of tumor-associated DNA methylation and m6A epitranscriptomic features.
- interventionNames
- Diagnostic Test: DNA Methylation Profiling
- Diagnostic Test: m6A Epitranscriptomic Profiling
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer. * Availability of archived tumor tissue suitable for molecular profiling. * Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both. * Availability of relevant clinicopathologic data. * Availability of survival or follow-up information when applicable. * Age 18 years or older at diagnosis or tissue collection. Exclusion Criteria: * Insufficient tissue quantity or quality for molecular profiling. * Inadequate DNA or RNA quality for sequencing or molecular assay preparation. * Missing essential clinicopathologic information required for analysis. * Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site. * Patients who do not meet institutional review board or consent requirements, if applicable.
References
Publications (0)
Data not yet available